Therapeutic or preventing agent for multiple sclerosis including indole compound
Inventors
Ueda, Yoshifumi • Kurimoto, Takafumi • UESATO, Naofumi
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12458646-B2
Publication Date
2025-11-04
Expiration Date
Abstract
The present invention provides a therapeutic agent or prophylactic agent for multiple sclerosis, containing N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-indol-6-yl]-N-methyl-(2S)-2-(morpholin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.
Core Innovation
The invention relates to a pharmaceutical use for treating multiple sclerosis in a human subject in need thereof by administering a compound represented by a specified chemical structural formula, or a pharmaceutically acceptable salt thereof. The human subject has had a prior treatment with FTY-720, and the prior treatment with FTY-720 is clinically insufficient.
The invention further provides methods for suppressing the progression of a physical disorder of multiple sclerosis in a human subject by administering a therapeutically effective amount of the same compound or pharmaceutically acceptable salt. The disclosed scope includes multiple sclerosis types and symptom-based selections, including relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS).
The disclosed symptom presence includes, for example, feeling of weakness, ataxia, sensory neuropathy, dysuria, dyschezia, mental disorder, and memory disorder, with at least one symptom criterion. The document describes supporting rationale using EAE animal models with reduced clinical severity versus vehicle and comparison to FTY-720, including adoptive transfer EAE and EAE induction using MOG.
Claims Coverage
The document includes two independent claims, each grounded on administering the specified Compound A (or a pharmaceutically acceptable salt) to a human subject with multiple sclerosis after clinically insufficient prior treatment with FTY-720. Across the independent claims, the inventive coverage focuses on treating multiple sclerosis and suppressing progression of a physical disorder of multiple sclerosis, with dependent claims narrowing to specific MS subtypes, symptom presence, and salt identity as monohydrochloride.
FTY-720 clinically insufficient multiple sclerosis treatment by administering Compound A or pharmaceutically acceptable salt
A method for treating multiple sclerosis in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of a compound represented by the specified chemical structural formula, or a pharmaceutically acceptable salt thereof, wherein the human subject has had a prior treatment with FTY-720 and wherein the prior treatment with FTY-720 is clinically insufficient.
FTY-720 clinically insufficient suppression of progression of physical disorder in multiple sclerosis by administering Compound A or pharmaceutically acceptable salt
A method for suppressing the progression of a physical disorder of multiple sclerosis in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of a compound represented by the specified chemical structural formula, or a pharmaceutically acceptable salt thereof, wherein the human subject has had a prior treatment with FTY-720 and wherein the prior treatment with FTY-720 is clinically insufficient.
Overall claim coverage is centered on therapeutic administration of the specified chemical structural formula compound (Compound A) or pharmaceutically acceptable salts to human subjects with multiple sclerosis who previously received FTY-720 with clinically insufficient effect, with additional claim narrowing to MS subtypes, listed symptom presence, and salt identity as monohydrochloride.
Stated Advantages
Prolonging remission of multiple sclerosis.
Preventing recurrence.
Suppressing progression of physical disorder associated with multiple sclerosis.
Reducing clinical severity in EAE versus vehicle, including comparison to FTY-720.
Documented Applications
Therapeutic and/or prophylactic use for multiple sclerosis in a human subject in need thereof, including relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS), particularly where prior treatment with FTY-720 is clinically insufficient.
Suppression of the progression of a physical disorder of multiple sclerosis in a human subject with clinically insufficient prior treatment with FTY-720.
Use-case selection based on at least one symptom of multiple sclerosis chosen from weakness, ataxia, sensory neuropathy, dysuria, dyschezia, mental disorder, and memory disorder.
EAE model support described for rationale, including adoptive transfer EAE with MOG-related induction and comparison to vehicle and FTY-720.
Interested in licensing this patent?